clinical trial · NCT07275606
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
ViiV Healthcare·phase2·not yet recruiting·n = 66
HIV InfectionsOral CABIM CAB LA
brief summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of cabotegravir in neonates exposed to human immunodeficiency virus (HIV)-1.
started
Mar 17, 2026
primary completion
Oct 10, 2029
completion
Oct 10, 2029
last updated
Dec 10, 2025
official title
A Phase 1/2 Study of the Safety, Tolerability, and Pharmacokinetics of Cabotegravir in Neonates Exposed to HIV-1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol